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1ABSTRACT
Keratin 19 expression in hepatocellular carcinoma is regulated by 
fibroblast-derived HGF via MET-ERK1/2-AP1/SP1 axis
Hyungjin Rhee
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Young Nyun Park)
Background: Keratin 19 (KRT19) has been shown to be a stem/progenitor marker of 
liver cells and poor prognostic factor for hepatocellular carcinoma (HCC). We 
recently reported that HCCs with abundant fibrous stroma (scirrhous HCC) show 
expression of KRT19. The regulatory mechanism of KRT19 in HCC, however, is not 
well understood.
Materials and methods: We investigated regulatory mechanisms of KRT19 
expression in HCC using an in vitro model of paracrine interactions between hepatic 
stellate cell (hTERT-HSC) and HCC cell lines (HepG2, SNU423). The regulatory 
axis of KRT19 was validated in tissue microarrays of human HCC tissue (n=339).
Results: The hepatic stellate cell line (hTERT-HSC) upregulated transcriptional and 
translational levels of KRT19 in both HCC cell lines (HepG2, SNU423) via paracrine 
interaction. Conditioned media (CM) from hTERT-HSC upregulated KRT19 
expression via activation of the MEK-ERK1/2 pathway. Hepatocyte growth factor 
(HGF) from the hTERT-HSC CM and subsequent activation of c-MET in the HCC 
cell lines were responsible for ERK1/2 activation and KRT19 upregulation. 
Luciferase reporter assay revealed that AP1 and SP1 binding sites in KRT19 promoter 
2are important to transgene expression. AP1 family proteins, JUN and FOSL1, and 
SP1, which are downstream transcriptional activators of ERK1/2, were found to be 
activators of KRT19 gene expression. Multikinase inhibitors, including sorafenib and 
crizotinib, which inhibit MET and ERK1/2 pathways, eliminated the previously 
observed, CM-induced upregulation of KRT19. In human HCC tissue, the expression 
of KRT19 was correlated with MET and FOSL1 expression, as well as amounts of 
tumor fibrous stroma.
Conclusion: The expression of KRT19 in HCC is regulated by fibrous tumor stroma 
therein via a HGF-MET-ERK1/2-AP1 and SP1 axis. Our results provide insights into 
the molecular background of aggressive, KRT19-positive HCC.
Key words: Keratin 19, Cancer-associated fibroblast, Hepatocyte growth factor, MET 
protooncogene, Fos-related antigen 1
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Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Young Nyun Park)
I. INTRODUCTION
Keratin 19 (KRT19) is a small, type I cytokeratin (approximately 40kDa); it lacks 
the tail domain common among cytokeratins.1 KRT19 is normally expressed in the 
simple epithelia of various organs, including the breast, trachea, gastrointestinal track, 
and pancreas.2,3 It is also expressed in neoplastic tissues, including carcinomas of the 
breast, lung, stomach, colon, and pancreas.4 In normal liver tissue, hepatocytes 
express KRT8 and KRT18, while cholangiocytes and bipotential hepatic progenitor
cells additionally express KRT7 and KRT19.5
Like normal hepatocytes, most of hepatocellular carcinomas (HCCs) do not 
express KRT19. Those that do expresses KRT19 (10-28% of HCCs)6-8 show invasive 
phenotype8,9 and they also were related with poor outcomes when treated with hepatic 
resection,8,10 or radiofrequency ablation.11 Interestingly, KRT19 protein expression 
or KRT19 expression-related signature has emerged as predictors of HCC recurrence 
and survival after liver transplantation.12,13 Accordingly, KRT19 expression is 
4considered a marker of poor prognosis in HCC patients treated with all three currently 
available, curative treatments of HCC.14,15
Despite the clinical significance of KRT19 expression in HCC, the regulatory 
mechanism of KRT19 expression is not well understood. Previously, a subset of 
KRT19-positive HCCs were considered to be of hepatic progenitor cell origin, in 
which KRT19 is normally expressed.16 However, recent lineage-tracing rodent 
models of HCC demonstrated that KRT19-positive HCC cells were of mature 
hepatocyte origin and were not observed in the early clonal expansion of 
hepatocarcinogenesis.17,18 These results suggest that KRT19 expression is an acquired 
phenotype during hepatocarcinogenesis, and thus, it is plausible that KRT19 
expression might be regulated by microenvironmental factors. We previously 
reported that HCCs with abundant fibrous stroma (namely, “scirrhous HCC”) 
commonly express KRT19.19 In light of these results, we hypothesized that KRT19 
expression in HCCs might be regulated by fibrous stromal components therein.
Cancer-associated fibroblasts have been shown to contribute to an aggressive 
cancer phenotype, facilitating invasiveness, proliferation, and immune suppression.20
In HCC, cancer-associated fibroblasts are recruited and transdifferentiated from 
peritumoral myofibroblasts by crosstalk with tumor cells.21 Hepatic myofibroblasts 
are a heterogenous group of cells, and activated hepatic stellate cells are one of major 
source of hepatic myofibroblasts.22,23
Here, we established an in vitro interaction model of HCC cells and cancer-
associated fibroblasts using HCC and hepatic stellate cell lines. We discovered that 
hepatic stellate cell-derived hepatocyte growth factor (HGF) and subsequent 
activation of the MET-MEK-ERK1/2 pathway activates KRT19 transcription via 
AP1 (JUN/FOSL1) and SP1 transcription factors. This regulatory axis was validated 
in a large HCC cohort (n=339) with immunohistochemical staining. Our results 
provide better understanding of the molecular background of KRT19-positive HCCs.
5II. MATERIALS AND METHODS
1. Cell lines and reagents
HepG2, Hep3B, and PLC/PRF/5 lines were purchased from American Type 
Culture Collection (ATCC; Manassas, VA, USA), and Huh7, SNU182, SNU423, and 
SNU475 cell lines were purchased from Korean Cell Line Bank (Seoul, Korea). 
hTERT-HSC and LX-2 cell lines were obtained as gifts from David Brenner24 and 
Scott Friedman25, respectively. Cell lines were maintained in Dulbecco Modified 
Eagle Medium supplemented with 10% fetal bovine serum and 
penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). U0126 and sorafenib were 
purchased from Cell Signaling Technology (Danvers, MA, USA); mithramycin A 
was purchased from Tocris Bioscience (Bristol, UK); and SCH772984, SU11274, 
PHA-665752, and crizotinib were purchased from Selleckchem (Houston, TX, USA).
2. Generation of conditioned media and enzyme-linked immunosorbent assay 
(ELISA)
For conditioned media generation, two hepatic stellate cell lines (hTERT-HSC, 
LX-2) were seeded on 150-mm plates at a confluency of 70-80%, incubated with 
complete media for 3 days, filtered through a 0.45-μm syringe filter, and stored at -
20°C until ready for use. Concentrations of HGF were determined with a human HGF 
ELISA kit purchased from R&D systems (Minneapolis, MN, USA).
3. Quantitative real time PCR
Total RNA was extracted from cell line samples with a RNeasy Mini kit (Qiagen, 
Valencia, CA, USA). RNA was quantified with Nanodrop (Thermo Scientific, 
Pittsburgh, PA, USA), and a total of 1 μg of RNA was subsequently subjected to 
DNase I treatment and subsequent cDNA synthesis using M-MLV Reverse 
Transcriptase (Invitrogen). Quantitative real-time PCR reactions were performed on 
the Step One Plus system using Taqman or SYBR-based detection reagents (Applied 
Biosystems, Foster City, CA, USA). The primers and probe sets used in the PCR 
6reactions are listed in Table 1. All quantitative real-time PCR reactions were carried 
out with the standard curve method, unless otherwise described. Serially diluted 
HepG2 cDNA was used as standard for quantitation.
7Table 1. Primer sequences for PCR reaction
Gene Forward primer Reverse primer Probe
Primer/probe sets for probe-based detection
ACTB GTCCCCCAACTTGAGATGTATG
AAGTCAGTGTACAGGTAAG
CC
CTGCCTCCACCCACTCCCA
KRT19 AGCCACTACTACACGACCAT
TTGGTTCGGAAGTCATCTG
C
TGCCACCATTGAGAACTCCAG
GATT
Primer sets for SYBR-based detection
ACTB CACCATTGGCAATGAGCGGTTC
AGGTCTTTGCGGATGTCCA
CGT
JUN CCTTGAAAGCTCAGAACTCGGAG
TGCTGCGTTAGCATGAGTT
GGC
JUNB CGATCTGCACAAGATGAACCACG
CTGCTGAGGTTGGTGTAAA
CGG
FOS GCCTCTCTTACTACCACTCACC
AGATGGCAGTGACCGTGGG
AAT
FOSB TCTGTCTTCGGTGGACTCCTTC
GTTGCACAAGCCACTGGAG
GTC
JUND ATCGACATGGACACGCAGGAGC
CTCCGTGTTCTGACTCTTGA
GG
FOSL1 GGAGGAAGGAACTGACCGACTT
CTCTAGGCGCTCCTTCTGCT
TC
FOSL2 AAGAGGAGGAGAAGCGTCGCAT
GCTCAGCAATCTCCTTCTG
CAG
8(continued)
Gene Forward primer Reverse primer Probe
Primer sets for SYBR-based detection
SP1 ACGCTTCACACGTTCGGATGAG TGACAGGTGGTCACTCCTCATG
Primer sets for chromatic immunoprecipitation assay
AP1 (-2021 from TSS) TCAGGCCAGAAAAACAGAGC AGAGCCCAAGAGGGAGAAAG
SP1 (-72 from TSS) GCCCATATTTGCTCTCAGGA GAGCAACCCTGGTCTCAGAA
94. Western blot analysis and phospho-receptor tyrosine kinase array
Cell line samples were washed with phosphate-based saline two times and then 
lysed with cell extraction buffer (Invitrogen). Protein concentrations were determined 
with a BCA Protein Assay kit (Thermo Scientific). Next, 30 μg of lysate were loaded 
to precast Bis-Tris gel, after which electrophoresis and dry blotting to a PVDF 
membrane were performed according to the manufacturer’s instructions (Invitrogen). 
The membrane was blocked for 30 mins in room temperature (tris-based saline, 0.1% 
tween 20, 5% bovine serum albumin), and then incubated with primary antibody for 
4°C overnight. Protein expression was detected with horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technology), chemiluminescent 
substrate (Thermo Scientific), and X-ray film (AGFA). The antibodies used in the 
western blot analysis are listed in Table 2. The phospho-receptor tyrosine kinase array 
was purchased from R&D systems and performed in accordance with the 
manufacturer’s protocol.
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Table 2. List of antibodies
Antibody Source Application
β-actin (mouse mAb, C-4)
Santa Cruz Biotechnology (Santa 
Cruz, CA, USA)
Western blot
phospho-Akt (Ser473, rabbit mAb, clone 
D9E)
Cell signaling (Danvers, MA, 
USA)
Western blot
Akt (rabbit mAb, clone C67E7)
Cell signaling (Danvers, MA, 
USA)
Western blot
phospho-ERK1/2 (Thr202/Tyr204, rabbit 
mAb, clone D13.14.4E)
Cell signaling (Danvers, MA, 
USA)
Western blot
ERK1/2 (rabbit mAb, clone 137F5)
Cell signaling (Danvers, MA, 
USA)
Western blot
FAP (rat mAb, clone D8) Vitatex (Stony Brook, NY, USA) Western blot
phospho-FOSL1 (Ser265, rabbit mAb, clone 
D22B1)
Cell signaling (Danvers, MA, 
USA)
Western blot
FOSL1 (rabbit mAb, clone D80B4)
Cell signaling (Danvers, MA, 
USA)
Western blot
FOSL1 (mouse mAb, C-12)
Santa Cruz Biotechnology (Santa 
Cruz, CA, USA)
Chromatin immunoprecipitation, 
Immunohistochemistry
HGF (goat pAb)
R&D system (Minneapolis, MN, 
USA)
Neutralization, Immunofluorescence
HGF (rabbit pAb)
Sigma-Aldrich (St. Louis, MO, 
USA)
Immunohistochemistry
phospho-JNK (Thr183/Tyr185, rabbit mAb, 
clone 81E11)
Cell signaling (Danvers, MA, 
USA)
Western blot
JNK (rabbit pAb)
Cell signaling (Danvers, MA, 
USA)
Western blot
11
(continued)
Antibody Source Application
phospho-JUN (Ser73, rabbit mAb, clone 
D47G9)
Cell signaling (Danvers, MA, USA)
Western blot, Chromatin 
immunoprecipitation
JUN (rabbit mAb, clone 60A8) Cell signaling (Danvers, MA, USA) Western blot
KRT19 (mouse mAb, clone RCK108)
Abcam  (Cambridge, MA, USA) or 
Dako (Glostrup, Denmark)
Western blot, Immunohistochemistry
Lamin B (rabbit pAb) Abcam  (Cambridge, MA, USA) Western blot
phospho-MET (Tyr1234/1235, rabbit 
mAb, clone D26)
Cell signaling (Danvers, MA, USA) Western blot
MET (rabbit mAb, clone D1C2) Cell signaling (Danvers, MA, USA) Western blot, Immunofluorescence
MET (rabbit mAb, clone SP44)
Ventana Medical Systems, Inc., 
Tucson, AZ, USA
Immunohistochemistry
Myc-Tag (mouse mAb, clone 9B11) Cell signaling (Danvers, MA, USA) Western blot
phospho-p38 (Thr180/Tyr182, rabbit 
mAb, clone D3F9)
Cell signaling (Danvers, MA, USA) Western blot
p38 (rabbit mAb, clone D13E1) Cell signaling (Danvers, MA, USA) Western blot
α-SMA (mouse mAb, clone 1A4) Dako (Glostrup, Denmark) Western blot, Immunohistochemistry
SP1 (rabbit mAb, clone D4C3) Cell signaling (Danvers, MA, USA)
Western blot, Chromatin 
immunoprecipitation
phospho-STAT3 (Tyr705, rabbit mAb, 
clone D3A7)
Cell signaling (Danvers, MA, USA) Western blot
STAT3 (mouse mAb, clone 124H6) Cell signaling (Danvers, MA, USA) Western blot
Vimentin (mouse mAb, clone Vim 3B4) Dako (Glostrup, Denmark) Western blot
12
5. Plasmids, siRNA, and transfection
pLenti-puro, pLenti-MetGFP, Tet-pLKO-puro, psPAX2, and pMD2.G were 
purchased from Addgene (Cambridge, MA, USA). pLenti-puro was obtained as a gift 
from Ie-Ming Shih (Addgene plasmid # 39481),26 pLenti-MetGFP a gift from David 
Rimm (Addgene plasmid # 37560). Tet-pLKO-puro a gift from Dmitri Wiederschain 
(Addgene plasmid # 21915),27 and psPAX2 and pMD2.G gifts from Didier Trono 
(Addgene plasmid # 12259, # 12260). Empty expression vectors, pCMV-myc and 
p3xFLAG-CMV-10 were purchased from Clontech (Palo Alto, CA, USA) and 
Sigma-Aldrich (St. Louis, MO, USA), respectively. We cloned the coding DNA 
sequence (CDS) of the MET gene from pLenti-MetGFP, and inserted to pLenti-puro 
vector (pLenti-puro-MET). The CDSs of MEK1 and ERK1 were amplified from 
complementary DNA (cDNA) from HepG2 and cloned into pCMV-myc (pCMV-
myc-MEK1, pCMV-myc-ERK1). To obtain a constitutively active form of MEK1, 
we substituted two serine residues (S218, S222) to aspartate using site-specific 
mutagenesis (pCMV-myc-MEK1 S218D/S222D). The CDSs of JUN, FOSL1, and 
SP1 were cloned from HepG2 cDNA into p3xFLAG-CMV-10 vector. The 
heterodimeric fusion protein of JUN and FOSL1 (JUN~FOSL1)28 were generated by 
inserting glycine rich linker between the CDSs of JUN and FOSL1 and then also 
cloned into p3xFLAG-CMV-10 vector. All siRNA or shRNA target sequences were 
taken from the RNAi consortium collection (Sigma-Aldrich); they are listed in Table
3. Transient transfection of plasmid or siRNA was performed with Lipofectamine 
3000 reagent according to the manufacturer’s instructions.
To establish inducible HGF-knockdown hTERT-HSC, we inserted synthesized 
oligo harboring shRNA sequences to Tet-pLKO-puro vector. Lentiviruses were
produced in HEK293FT cells (Invitrogen) with Tet-pLKO-puro, psPAX, and 
pMD2.G plasmids and Lipofectamine 3000 reagent. The virus transduced hTERT-
HSC cell lines were selected with puromycin (1 μg/mL). For HGF knockdown, 1 
μg/mL of doxycycline was treated for 48 hrs.
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Table 3. shRNA/siRNA target sequences for gene knockdown
Name Type Target sequence etc
shHGF-1 shRNA GTGATACCACACCTACAATAG
Cloned to Tet-
pLKO-puro 
vector
shHGF-2 shRNA TTTGTCCGAGTAGCATATTAT
Cloned to Tet-
pLKO-puro 
vector
siJUN-1 siRNA AGATGGAAACGACCTTCTA
siJUN-2 siRNA GTCATGAACCACGTTAACA
siJUND-1 siRNA AGCATGCTGAAGAAAGACGC
siJUND-2 siRNA GAAAGTCCTCAGCCACGTCAA
siFOS-1 siRNA GCGGAGACAGACCAACTAGAA
siFOS-2 siRNA ACCTATCTGGGTCCTTCTATG
siFOSL1-1 siRNA GTACGTCGAAGGCCTTGTGAA
siFOSL1-2 siRNA CTGTACCTTGTATCTCCCTTT
siFOSL2-1 siRNA GCAGTGAGTATTGGAAGACTT
siFOSL2-2 siRNA CACGGCCCAGTGTGCAAGATT
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6. Dual luciferase assay
Two reporter plasmids, pGL4.10 and pNL1.1.TK, and a dual luciferase assay kit 
were purchased from Promega (Madison, WI, USA). The 5’ flanking region of 
KRT19 gene, -2885 from +41, relative to the transcription start site (corresponds to -
2946 from -20 relative to first ATG), was amplified from HepG2 genomic DNA and 
cloned into pGL4.10 vector. Using PCR, the KRT19 promoter insert was serially 
deleted at the interval of 100-400 base pairs, from the 5’ end. To investigate
functionally relevant transcription factor binding sites, the putative transcription 
factor binding sites were mutated using site-specific mutagenesis. All promoter 
constructs were sequenced to verify the sequence. HepG2 and SNU423 cells were 
seeded to 96-well white plates at a density of 10,000 cells per well. A total of 50 ng 
of reporter plasmids were transfected with Lipofectamine 3000 reagent at the 
following ratio of pGL4 vector: pNL vector = 500 : 1. At 48 hrs post transfection, 
dual luciferase assays were performed according to the manufacturer’s protocol.
7. Oligo pull-down and chromatic immunoprecipitation assay
For oligo pull-down assay, 26 base-pair-long, double-stranded KRT19 promoter 
fragments containing the AP1 binding site (5’-
ATAAGGGAATGACTCAGAGCTGACCA-3’ biotin) or a mutant AP1 binding site 
(5’-ATAAGGGAAAAACCCGGAGCTGACCA-3’ biotin) were synthesized. 
KRT19 promoter fragments containing the SP1 binding site (5’–
CTCAGATATCCGCCCCTGACACCATT–3’ biotin) or a mutant SP1 binding site 
(5’– CTCAGATATCCGTTCCTGACACCATT– 3’ biotin) was also synthesized. Next,
100 pico-mole of double-stranded DNA fragment was incubated with 250 μg 
streptavidin-conjugated magnetic bead (Invitrogen) and 500 μL of binding/wash 
buffer (5 mM Tris-HCl [pH 7.4], 0.5 mM EDTA, 1M NaCl) in a rotator. A total of 1
mg of nuclear lysate from HepG2 or SNU423 was pre-cleared with 125 μg of 
streptavidin-conjugated magnetic beads (Invitrogen) and 2.5 μg of Poly(dI-dC) 
(Sigma-Aldrich). The promoter fragment-magnetic bead complex was washed and 
then incubated with pre-cleared nuclear lysate for 2 hrs in a cold room. The magnetic 
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beads were washed five times with binding/wash buffer, and the DNA-binding 
proteins were eluted by boiling in 2X LDS sample buffer (Invitrogen) and analyzed 
by western blot.
Chromatic immunoprecipitation assay was carried out with a SimpleChIP Plus 
enzymatic chromatic IP kit (Cell signaling) following the manufacturer’s instruction. 
The primer sets used in the PCR reaction are listed in Table 1.
8. Immunofluorescence staining
For immunofluorescence staining, cells on cell culture slide (SPL Life Sciences, 
Pocheon, Republic of Korea) were fixed with 4% formaldehyde, washed with PBS, 
and permeabilized and blocked with blocking buffer (PBS, 1% BSA, and 0.3% Triton 
X-100). They were then incubated with primary antibody with blocking buffer at 4°C 
overnight. After washing, the slides were incubated with fluorochrome-conjugated 
secondary antibodies (Invitrogen) for 1 hr at room temperature. The slides were then 
washed and mounted with antifade mounting medium with DAPI counterstain 
(Vector Laboratories, Burlingame, CA, USA).
9. Human hepatocellular carcinoma samples, and clinicopathologic and 
immunohistochemical analyses
We enrolled total 339 HCC patients who did not undergo any kind of preoperative 
treatment before hepatic resection. Consecutive HCC samples were obtained by 
hepatic resection between March 2006 and February 2011 at Severance Hospital, 
Yonsei University Medical Center. The clinicopathological characteristics of the 
cohort are described in Table 4. The representative paraffin-embedded sections of 
HCC were used for tissue microarray construction and immunohistochemical 
analysis. For TMA construction, two core biopsies of 2 mm in diameter were taken 
from individual HCC donor paraffin blocks and arranged into recipient TMA blocks 
using a trephine apparatus (Superbiochips Laboratories, Seoul, Korea). 
Immunohistochemical staining for KRT19, HGF, MET, and FOSL1 was 
performed using an automated staining system (Ventana Medical Systems, Inc., 
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Tucson, AZ, USA). α-smooth muscle actin (αSMA) was stained using an Envision 
kit (Dako) according to the manufacturer’s instructions. All slides were counter-
stained with hematoxylin. Detailed information on criteria for immunohistochemical 
analysis is described in Table 5.
The clinical outcomes of the patients were retrospectively obtained by reviewing 
the electronic medical record system at Severance Hospital. The last update of the 
patient cohort was September 2016. The endpoints were defined as follows. Disease-
specific survival was defined as time from surgery to death in patients with HCC
involving >50% of the liver, HCC with extensive portal vein tumor thrombosis, or 
HCC with extrahepatic metastasis.29 Disease-free survival was defined as the time 
from surgery to initial diagnosis of recurrence regardless of location. This study was 
approved by the Institutional Review Board of Severance Hospital, and the 
requirement for informed consent was waived.
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Table 4. Clinicopathologic characteristics of hepatocellular carcinoma cohort 
(n=339)
Clinicopathologic features Value
Age (year) 56 (48-63)
Gender (male/female) 277 (82%) / 62 (18%)
Etiology (hepatitis B/hepatitis 
C/alcohol/unknown)
277 (82%) / 18 (5%) / 15 (4%) / 
29 (9%)
Cirrhosis 187 (55%)
Serum aspartate transaminase (IU/L) 30 (24-41)
Serum alanine transaminase (IU/L) 31 (22-45)
Serum albumin (g/dL) 4.4 (4.1-4.7)
Serum platelet (1000/μL) 163.0 (131.0-208.0)
Serum alpha-fetoprotein (IU/mL) 1 22.8 (4.3-221.3)
Serum PIVKA-II (AU/mL)2 80.0 (32.0-491.8)
Tumor pathology
Diameter of largest tumor (cm) 3.0 (2.2-4.5)
Differentiation (Edmonson-Steiner grade 
I/II/III)
26 (8%) / 246 (73%) / 67 (20%) 
Capsule formation (absent/partial/complete) 59 (17%) / 182 (54%) / 98 (29%) 
Microvascular invasion 194 (57%)
Tumor multiplicity 44 (13%)
TNM stage (I/II/III) 122 (36%) / 200 (59%) / 17 (5%) 
Preoperative treatment (none / preoperative 
locoregional therapy)
339 (100%) / 0 (0%)
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Table 5. Criteria for immunohistochemistry analysis
Antibody Score Definition
KRT19
Negative / 
Positive
Positive: cytoplasmic expression, 
moderate or strong intensity, ≥5% of 
tumor cells
HGF, MET
Negative / 
Positive
Positive: membranous expression, 
moderate or strong intensity, ≥5% of 
tumor cells
FOSL1
Negative / 
Positive
Positive: nuclear expression, moderate 
or strong intensity, ≥5% of tumor cells
αSMA-positive cancer 
associated fibroblast
Proportion 
(%)
Stromal fibroblast proportion in tumor 
tissue, moderate or strong intensity
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10. Statistical analysis
Statistical analyses were performed using SPSS software (version 23.0, SPSS Inc., 
Chicago, IL, USA). Mann-Whitney U test, chi-square test, or Fisher’s exact test were 
used as deemed appropriate. Survival analyses were performed by the Kaplan-Meier 
method and log rank test.
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III. RESULTS
1. KRT19 expression is upregulated by paracrine factors from hepatic stellate 
cells
Correlation between fibrous stromal components and KRT19 expression was 
confirmed in our TMA cohort (n=339). Expression of KRT19 protein increased along 
with increases in α-smooth muscle actin (αSMA)-positive cancer-associated 
fibroblasts (Figure 1A and B).
To establish an in vitro model of interactions between cancer-associated fibroblasts
and epithelial tumor cells in HCC, we tested two hepatic stellate cell lines; hTERT-
HSC and LX-2. hTERT-HSC showed more fibroblast-like morphology, and higher 
expression of fibroblast activation-related markers including FAP and αSMA,30
compared to LX-2 (Figure 2A and B). Interestingly, conditioned media (CM) from 
hTERT-HSC induced increased expression of KRT19 in HepG2, whereas CM from 
LX-2 did not (Figure 2C).
Next, we treated HepG2 and SNU423 cell lines with CM from hTERT-HSC for 
12-72 hrs. The CM from hTERT-HSC increased mRNA and protein expression of 
KRT19, and the difference was apparent at 24-72 hrs (Figure 3A). We also conducted 
indirect co-culture using permeable cell culture inserts of 1-μm pore size. Sharing of 
the culture media between the HCC cell lines and hTERT-HSC increased expression 
of KRT19 mRNA and protein in HepG2 and SNU423 (Figure 3B). Both CM 
treatment and indirect co-culture resulted in similar features of cell scattering and 
elongation (Figure 3C). These results suggest that paracrine factors from hTERT-
HSC regulate the expression of KRT19 in HCC cell lines.
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Figure 1. Correlation between cancer-associated fibroblast and KRT19 
expression in hepatocellular carcinoma (HCC) tissues. A) Representative cases of 
HCC with or without α-smooth muscle actin (αSMA)-positive cancer-associated 
fibroblasts. B) Correlation between αSMA-positive cancer-associated fibroblast and 
KRT19 protein expression.
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Figure 2. Characteristics of hepatic stellate cell lines. A) Cell morphology of two 
hepatic stellate cell lines, hTERT-HSC and LX-2. B) Western blot analysis of 
fibroblast activation-related markers in hTERT-HSC and LX-2. C) Protein 
expression change of phospho-ERK1/2 and KRT19 of HepG2, following treatment 
with conditioned media (CM) from hTERT-HSC or LX-2.
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Figure 3. KRT19 expression in HCC is upregulated by paracrine factors from 
hepatic stellate cells. A) mRNA and protein expression level of KRT19 after 
hTERT-HSC conditioned media (CM) treatment. The HCC cells (HepG2 and 
SNU423) were harvested at the indicated times, and mRNA and protein expression 
was analyzed by qRT-PCR or western blot. Bar graph represents mean ± SD. B) 
mRNA and protein expression levels of KRT19 after co-culture with hTERT-HSC. 
C) Morphologic changes in HepG2 and SNU423 induced by co-culture with hTERT-
HSC or CM from hTERT-HSC.
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2. Conditioned media regulates KRT19 expression through MEK-ERK1/2 
pathway
KRT19-positive HCC is associated with invasive phenotype and poor prognosis. 
Accordingly, we hypothesized that KRT19 expression would be regulated by an
oncogenic signaling pathway. To investigate the signaling pathways intervening in 
the upregulation of KRT19 upon treatment with CM from hTERT-HSC, we screened 
the activation statuses of representative oncogenic signaling pathways, including 
MAPK, AKT, and STAT3. The CM treatment induced the phosphorylation of 
ERK1/2 in both HepG2 and SNU423 cells and STAT3 in HepG2 only. Other 
signaling pathways, including p38 MAPK, JNK, and AKT, were unchanged (Figure 
4A). STAT3 inhibitor (S3I-201) treatment decreased KRT19 expression in HepG2
cells, but not in SNU423 cells, suggesting that the STAT3 pathway is not a common 
regulator of KRT19 for both cell lines (Figure 4B).
When the MEK-ERK1/2 pathway was inhibited by MEK inhibitor (U0126) or 
ERK1/2 inhibitor (SCH772984),31 the observed CM-treatment-induced KRT19 
upregulation vanished in HepG2 and SNU423 cells (Figure 5A). KRT19 expression 
also increased with 12-O-Tetradecanoylphorbol-13-acetate (TPA) treatment, and 
combination of MEK or ERK1/2 inhibitor with TPA decreased KRT19 expression 
(Figure 5B). To further confirm the regulation of KRT19 expression by MEK-
ERK1/2 pathway, constitutively active form of MEK1 (S218D/S222D) and ERK1 
wild type were overexpressed in two HCC cell lines.32 To obtain more apparent 
results, we used HepG2 and SNU475 cells in an overexpression experiment, instead 
of SNU423, because the transfection efficiency of SNU423 is quite low, compared to 
other cells (Figure 5C). The overexpression of MEK1 S218D/S222D and ERK1 
increased KRT19 expression by two- to six-fold (Figure 5D). Taken together, CM 
increased KRT19 expression in HCC cell lines through MEK-ERK1/2 pathway.
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Figure 4. Screening of activation status of selected oncogenic pathways after 
conditioned media (CM) treatment. A) The activation status of selected oncogenic 
pathways in HepG2 and SNU423 cells by CM from hTERT-HSC. B) mRNA and 
protein levels of KRT19 after 24 hrs CM treatment combined with/without the
STAT3 inhibitor SI3-201 in HepG2 and SNU423 cells. mRNA and protein 
expression was analyzed by qRT-PCR or western blot. Bar graph represents mean ± 
SD.
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Figure 5. Conditioned media (CM) regulates KRT19 expression through the
MEK-ERK1/2 pathway. A) mRNA and protein level of KRT19 after CM treatment 
combined with/without MEK or ERK inhibitor. mRNA and protein expression was
analyzed by qRT-PCR or western blot. Bar graph represents mean ± SD. B) mRNA 
and protein levels of KRT19 after 24 hrs of treatment with 12-O-
Tetradecanoylphorbol-13-acetate (TPA) combined with MEK1 or ERK1/2 inhibitor. 
C) Transient protein expression by plasmid transfection, MEK1 (S218D/S222D), in 
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HepG2, SNU423, and SNU475 cells. The amounts of plasmid used in transfection 
(per 35mm dish) are indicated. D) mRNA and protein upregulation of KRT19 in 
HepG2 and SNU475, by transient expression of constitutively active MEK1 
(S218D/S222D) or ERK1. 
28
3. Hepatocyte growth factor (HGF) in hTERT-HSC conditioned media (CM) 
upregulates KRT19 via MET and MEK-ERK1/2 pathway
To specify which paracrine factor and receptor activates the MEK-ERK1/2 
pathway in HCC cells, we performed phospho-receptor tyrosine kinase array for
HepG2 and SNU423 cell lines. The results of the array reflected increased 
phosphorylation of three common receptors: MET, ALK, and FGFR3 (Figure 6A). 
We decided to further investigate MET and its well-known ligand, hepatocyte growth 
factor (HGF), since several reports have shown that HGF is secreted by cancer-
associated fibroblasts in HCC.30,33 We confirmed the activation of phosphorylated 
MET upon treatment with CM in HepG2 and SNU423 cells using western blot
(Figure 6B). HGF concentrations, determined by ELISA, were much higher in CM 
of hTERT-HSC (>10ng/mL), compared to CM from HepG2 and SNU423
(<0.2ng/mL) (Figure 6C). Treatment with recombinant HGF induced KRT19 
upregulation in both HCC cell lines, and combined treatment with MAPK inhibitors 
decreased HGF-induced KRT19 upregulation (Figure 6D). 
Additionally, HGF concentrations in CM from another hepatic stellate cell line, 
LX-2, were very low (<0.1ng/mL). The CM from hTERT-HSC (high HGF 
concentration) increased KRT19 expression, whereas CM from LX-2 (low HGF 
concentration) did not (Figure 7A). In addition, HCC cell lines with low MET 
expression, including SNU182 and PLC/PRF/5, showed low KRT19 expression 
(Figure 7B). The transient overexpression of MET in SNU475 increased phospho-
MET and phospho-ERK1/2, as well as KRT19 at the mRNA and protein levels. In 
PLC/PRF/5, overexpression of MET also increased phospho-MET and phospho-
ERK1/2 and mRNA levels of KRT19. Protein levels of KRT19 were undetectable
(Figure 7C).
To determine whether HGF is indeed responsible for CM-induced KRT19 
upregulation, we established a doxycycline-inducible knockdown version of hTERT-
HSC (hT-shHGF-1, hT-shHGF-2). Two days of doxycycline treatment (1μg/mL) 
prior to CM generation efficiently knockdowned HGF concentration (7.2 ng/mL vs.
0.17 ng/mL in hT-shHGF-1, 8.4 ng/mL vs. 0.13 ng/mL in hT-shHGF-2, Figure 8A). 
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Treatment of HepG2 and SNU423 cells with CM from hT-shHGF-1 or hT-shHGF-2 
without doxycycline upregulated KRT19 expression at both transcriptional and 
translational levels in the cells; treatment with CM from hT-shHGF-1 or hT-shHGF-
2 with doxycycline, however, did not (Figure 8B). Also, doxycycline reversed the 
CM-induced cell scatter in hT-shHGF-1 and 2 (Figure 8C). Further, HGF-
neutralization with anti-HGF immunoglobulin also reversed the CM-induced KRT19 
upregulation and cell scatter (Figure 8D and E). When MET selective inhibitors 
(SU11274 and PHA-665752) were combined with CM, the upregulation of KRT19 
also diminished (Figure 8F). Our result suggests that HGF paracrine signaling from 
hepatic stellate cells upregulates KRT19 via MET and the MEK-ERK1/2 pathway.
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Figure 6. Hepatocyte growth factor (HGF) upregulates KRT19 via MET and 
MEK-ERK1/2 pathway. A) The phosphorylation status of receptor tyrosine kinases 
of HepG2 and SNU423 with conditioned media (CM) from hTERT-HSC. The 
increased phosphorylation of three receptors (MET, ALK, and FGFR3) were 
commonly observed in HepG2 and SNU423 cells. B) Increased phosphorylation of 
MET following CM treatment was confirmed in HepG2 and SNU423 cells. C) HGF 
concentrations in CM from hTERT-HSC, HepG2, and SNU423 cells determined by 
enzyme-linked immunosorbent assay. D) mRNA and protein levels of KRT19 after 
HGF treatment combined with/without MEK or ERK inhibitor. mRNA and protein 
expression was analyzed by qRT-PCR or western blot. Bar graph represents mean ± 
SD.
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Figure 7. Hepatocyte growth factor (HGF) and MET expression in hepatic 
stellate cell lines and hepatocellular carcinoma (HCC) cell lines. A) HGF 
concentrations in complete media (DMEM+10% FBS) and conditioned media (CM) 
from hTERT-HSC and LX-2. KRT19 mRNA expression of HepG2 and SNU423, 
after 24 hrs of treatment with CM from hTERT-HSC and LX-2 cells. mRNA 
expression was analyzed by qRT-PCR. Bar graph represents mean ± SD. B) Western 
blot analysis of HCC cell lines, showing expression of phospho-MET, MET, 
phsopho-ERK1/2, and KRT19. C) mRNA and protein expression of KRT19 in 
SNU475 and PLC/PRF/5 cells, following transient expression of MET. The amounts
of plasmids used in transfection (per 35mm dish) were indicated.
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Figure 8. Inhibition of hepatocyte growth factor (HGF) – MET pathway 
downregulated KRT19 expression. A) HGF concentrations in complete media 
(DMEM+10% FBS), and conditioned media (CM) from hT-shHGF-1, hT-shHGF-2 
stable cell lines with/without doxycycline treatment. B) mRNA and protein levels of 
KRT19 after treatment with CM from hT-shHGF-1, hT-shHGF-2 stable cell lines 
with/without doxycycline treatment. mRNA and protein expressions was analyzed by 
qRT-PCR or western blot. Bar graph represents mean ± SD. C) Morphologic change 
of HepG2 and SNU423 induced by CM from inducible HGF knockdown stable cell 
lines established from hTERT-HSC; shHGF-1 and shHGF-2. D) mRNA expression 
of KRT19 in HepG2 and SNU423, following CM treatment combined with 
hepatocyte growth factor (HGF) neutralizing antibody. E) Morphologic change of 
HepG2 and SNU423 induced by CM from hTERT-HSC, combined with HGF 
neutralizing antibody. F) mRNA and protein levels of KRT19 after CM treatment 
combined with/without MET inhibitors.
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4. AP1 and SP1 transcription factor binding sites in KRT19 promoter are 
important to KRT19 expression
To determine important cis-regulatory elements in KRT19 promoter, we 
constructed luciferase reporter plasmids of approximately 3kb-long (-2885bp from 
+41bp relative to transcription start site) and its serial deletion mutants (Figure 9A). 
We measured the promoter activity of the constructs in HepG2 and SNU423 cells, 
which showed similar trends in promoter activity between the two. The promoter 
activity significantly decreased at two segments: between -2167 and -1968 and 
between -152 and -69. To confirm that those two promoter segments are truly 
important in KRT19 regulation, we also measured the promoter activity of segmental 
deletion constructs of Δ2167-1968 and Δ152-69. The constructs elicited a >70% 
decrease in promoter activity for Δ2167-1968 and >25% for Δ152-69 (Figure 9B). 
The putative transcription factor binding sites at -2167~-1968 and -152~-69 were 
searched in online programs (PROMO; http://alggen.lsi.upc.es, and Tfsitescan; 
http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl), the mutant constructs of AP1, MAZ, 
ELK, ETS, and SP1 binding sites were generated by site-specific mutagenesis (Figure 
4C). Of these mutant constructs, mutants of the -2021 AP1 site and -72 SP1 site 
demonstrated significantly reduced activity. Therefore, AP1 and SP1, which are 
known as downstream transcriptional activators of ERK1/2, were identified to be 
important in KRT19 regulation.
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Figure 9. AP1 and SP1 transcription factor binding sites in KRT19 promoter 
are important to KRT19 expression. A) Luciferase reporter assay result of KRT19 
promoter constructs. Approximately 3kb-long KRT19 promoter and its serial deletion 
constructs were tested in HepG2 and SNU423 cells, and the firefly luciferase results 
were normalized with thymidine kinase-promoter driven nano-Luc luciferase results. 
Bar graph represents mean ± SD. B) Luciferase reporter assay results of KRT19 
promoter constructs, in which -2167~-1967 or -152~-69 segments were deleted from 
full length KRT19 promoter using site-directed mutagenesis. C) Luciferase activity 
of mutant reporter plasmids, in which putative transcription factor binding sites were 
altered by site directed mutagenesis from full length KRT19 promoter.
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5. JUN, FOSL1, and SP1 are important regulators of KRT19 expression
The AP1 binding site sequence of -2021 in the KRT19 promoter (TGACTCA) is 
well known as a TPA-responsive element (TRE), to which various heterodimers of 
JUN and FOS family proteins could bind.34 To identify specific AP1 proteins that
regulate KRT19 in HCC cell lines, we performed siRNA screening for AP1 family 
members. At first, we screened the transcription levels of seven JUN and FOS genes, 
including JUN, JUNB, JUND, FOS, FOSB, FOSL1, and FOSL2. Among these seven 
genes, we selected JUN, JUND, FOSL1, and FOSL2, which showed relatively higher 
mRNA expression than the other JUN and FOS family genes (Figure 10A). Targeting 
these genes, transient knock-down with pooled two siRNAs was carried out, and the 
knock-down efficiency was greater than 80% in all genes (Figure 10B). JUN or 
FOSL1 knockdown commonly decreased KRT19 expression in HepG2 and SNU423 
cells (Figure 10C). To confirm that these results were not off-target effects of the
siRNAs, we transfected siRNAs separately. By transfection of siJUN-1, siJUN-2, 
siFOSL1-1, and siFOSL1-2, JUN and FOSL1 were successfully knockdowned at the
transcriptional and translational levels, and declines in KRT19 mRNA followed in 
both HepG2 and SNU423 cells (Figure 10D and E).
With SP1 inhibitor (mithramycin A) treatment, KRT19 expression was decreased 
at the transcriptional and translational levels (Figure 11A). Conversely, 
overexpression of JUN, FOSL1, a heterodimeric fusion protein of JUN and FOSL1 
(JUN~FOSL1),28 and SP1 increased transcription level of KRT19 (Figure 11B). 
Reportedly, FOSL1 phosphorylation by ERK1/2 comprises proteasomal degradation 
and increases stability.35 In accordance with this previous reports, HepG2 and 
SNU423 cells treated with CM demonstrated increased phosphorylation and protein 
quantities of FOSL1 (Figure 11C).
To confirm the binding of JUN, FOSL1 and SP1 in KRT19 promoter, we 
performed DNA pull-down assay and chromatic immunoprecipitation (ChiP). We 
synthesized 26-bp-long biotinylated double-stranded DNA, mimicking the AP1 and 
SP1 sites of the KRT19 promoter that we noted (e.g., -2021 AP1 site, and -72 SP1 
site). Mutant biotinylated DNAs were also synthesized, in which AP1 or SP1 binding 
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motifs were altered. Western blot analyses of the DNA binding assay revealed the 
binding of JUN and FOSL1 to the -2021 AP1 site and SP1 binding to the -72 SP1 site 
in HepG2 and SNU423 cells (Figure 11D). ChiP assay confirmed the binding of JUN 
and FOSL1 at the -2021 AP1 site and SP1 at the -72 SP1 site (Figure 11E).
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Figure 10. siRNA screening of AP1 family genes demonstrated JUN and FOSL1 
is important regulators of KRT19 expression. A) Relative mRNA expression of 
AP1 family genes that could bind to TPA-responsive elements (TRE). mRNA 
expression was analyzed by qRT-PCR. Bar graph represents mean ± SD. B) KRT19 
mRNA expression after transfection of pooled two siRNAs targeting JUN, JUND, 
FOSL1, or FOSL2. C) The gene knock-down efficiencies of pooled two siRNAs 
39
targeting JUN, JUND, FOSL1, or FOSL2. D) KRT19 mRNA expression after 
transfection of siRNAs targeting JUN or FOSL1. E) The gene knock-down 
efficiencies of siRNAs targeting JUN or FOSL1. The efficiencies were determined 
by mRNA expression using qRT-PCR and western blot. 
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Figure 11. JUN, FOSL1, and SP1 are positive regulators of KRT19 expression. 
A) mRNA and protein level of KRT19 after 24 hrs of mithramycin A treatment 
combined with conditioned media (CM). mRNA and protein expression was analyzed 
by qRT-PCR or western blot. B) mRNA level of KRT19 after transient expression of 
JUN, FOSL1, JUN~FOSL1 (heterodimeric fusion protein consists of JUN, glycine-
rich tether, and FOSL1), and SP1. C) Changes in phosphorylation and quantity of 
JUN and FOSL1 following 24 hrs of CM treatment in HepG2 and SNU423 cells. D) 
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Western blot analysis of eluted DNA binding proteins from DNA pulldown assay. 
Nuclear extracts of HepG2 and SNU423 were incubated with DNA fragments 
mimicking -2021 AP1 or -72 SP1 binding sites of KRT19. E) Chromatin 
immunoprecipitation analysis of HepG2 and SNU423 demonstrate JUN and FOSL1 
binding at the -2021 AP1 site and SP1 binding at the -72 SP1 site.
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6. Crizotinib and sorafenib reduce the expression of KRT19
Two FDA-approved multikinase inhibitors, including crizotinib and sorafenib, 
were treated to HepG2 and SNU423 cells in combination with CM. Crizotinib can 
inhibit MET, as well as ALK and ROS1, and sorafenib can suppress MAPK pathway 
activation by inhibiting RAF.36,37 When crizotinib was treated without CM, 
transcription levels of KRT19 were not changed; however, when crizotinib was
treated in combination with CM, transcription levels of KRT19 decreased, compared 
to CM treatment alone. The protein levels of KRT19 showed similar patterns (Figure 
12A). Sorafenib treatment reduced the transcriptional and translational levels of 
KRT19 at the concentration of 10 μm with/without CM combination (Figure 12B).
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Figure 12. Crizotinib and sorafenib reduce the expression of KRT19. A) mRNA 
and protein level of KRT19 after treatment with conditioned media (CM) combined 
with/without crizotinib. mRNA and protein expression were analyzed by qRT-PCR 
or western blot. Bar graph represents mean ± SD. B) mRNA and protein levels of 
KRT19 after treatment with CM combined with/without sorafenib.
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7. HGF and/or MET expression is correlated with higher expression of KRT19 
and FOSL1 in human HCC samples
We assessed expression level of HGF, MET, and their downstream markers,
including FOSL1 and KRT19, in our HCC cohort. We also immunostained for
phospho-MET in HCC tissues, although none was detected (Figure 13). To assess the 
stability of phospho-MET in our in vitro model, CM-treated HepG2 was harvested at
various time points (0 to 30 mins) after media change (CM removed and changed to 
control media). Western blot analysis revealed a rapid decline in phospho-MET level, 
whereas MET, FOSL1 and KRT19 expression did not (Figure 14).
Interestingly, HGF expression was more predominant in tumor cells than in 
cancer-associated fibroblasts (Figure 15A). We also assessed the distribution of HGF 
in our in vitro model. We carried out immunofluorescent staining of HGF in cell lines. 
HGF is weakly stained in hTERT-HSC cells, but strongly stained in CM-treated HCC 
cell lines (Figure 15B). In HepG2 cells treated with CM, HGF was observed in 
intracellular space, serially increased in amounts, and co-localized with MET, 
suggesting that intracellular HGF in HepG2 came from CM and exists as a complex 
with MET (Figure 15C). In HCC tissue, HGF was observed in a cytoplasm
predominant pattern or membrane predominant pattern. The membrane predominant 
pattern of HGF was well-correlated with KRT19 expression, whereas the cytoplasmic 
pattern of HGF was not (Figure 16).
Therefore, membranous distributions of HGF and MET, nuclear expression of 
FOSL1, and cytoplasmic expression of KRT19 were scored (Figure 17A). The 
membranous distribution of HGF was well correlated with the presence of cancer-
associated fibroblasts (≥5%) (P=0.008), while the membranous MET expression was 
not (P=0.635) (Figure 17B). KRT19 expression was associated with HGF and FOSL1 
(Figure 17C, P<0.001, and P=0.001, respectively). When HCC cases were 
categorized according to HGF and MET status, FOSL1 and KRT19 expression was
most frequently observed in the HGF and MET double positive group and least 
frequently observed in the HGF and MET double negative group (Figure 17D, 
P<0.001 at both). HGF or MET positive patients showed favorable disease-specific 
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survival and disease-free survival, compared to HGF and MET double negative 
patients (Figure 17E, P=0.015 and P=0.011, respectively).
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Figure 13. Immunohistochemical staining results for phospho-MET. (A) 
Immunohistochemical staining results for two different rabbit monoclonal phospho-
MET antibodies in a representative tissue microarray slide. (B) Two representative 
cases with strong MET expression exhibited negative immunohistochemical staining 
result for phospho-MET.
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Figure 14. Rapid decline in phospho-MET levels after removal of conditioned 
media (CM). Western blot analysis of expressions of phospho-MET, MET, FOSL1, 
and KRT19 in HepG2 cells harvested at various time points (0 to 30 min).
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Figure 15. Distribution of hepatocyte growth factor (HGF) in hepatocellular 
carcinoma (HCC) tissues and the in vitro model. A) Representative HCC tissue 
samples with positive expression of HGF. B) Distribution of HGF in hepatic stellate 
cell lines and HCC cell lines, including HepG2 and SNU423. C) Distribution of HGF 
and MET in HepG2 cells, in various time points after conditioned media (CM) 
treatment.
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Figure 16. Two distinct patterns of subcellular localization of hepatocyte growth 
factor (HGF) in hepatocellular carcinoma (HCC) tissues. A) Representative HCC 
tissue samples with cytoplasmic or membranous distribution of HGF. B) The 
association between the subcellular localization pattern of HGF and KRT19 
expression.
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Figure 17. FOSL1 and KRT19 expression, and prognosis according to 
HGF/MET expression status. A) Representative hepatocellular carcinoma (HCC) 
tissue samples with positive expression of HGF, MET, FOSL1, and KRT19. B) The 
association between the αSMA-positive cancer-associated fibroblasts (≥5%) and 
HGF and MET expression. C) Association between KRT19 expression and HGF, 
MET, and FOSL1 expression. D) Expression of KRT19 in HCC patients subgrouped 
by HGF and MET status. E) Differences in disease-specific survival and disease-free 
survival between HGF or MET positive patients and HGF and MET-double negative 
patients.
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IV. DISCUSSION
KRT19 is known as one of most important prognostic factors in HCC. However, 
the regulatory mechanism of KRT19 expression is not well understood, nor is why 
KRT19-positive HCC harbors aggressive behavior. To unveil the regulatory 
mechanisms of KRT19 expression, we began our study by focusing on the association 
between abundant fibrous stroma and KRT19 expression in HCC, establishing an in 
vitro model of fibroblasts and epithelial tumor cells using hepatic stellate cell and 
HCC cell lines, and exploring the mechanisms of the KRT19 expression. Our study 
demonstrated that KRT19 in HCC is regulated by cancer-associated fibroblast-
derived HGF through a MET-ERK1/2-AP1 and SP1 axis. (Figure 18). Our results 
highlight the molecular background of clinically aggressive KRT19-positive HCC.
Previously, several studies have demonstrated the regulatory mechanisms of 
KRT19 expression in breast and pancreatic cancer cell lines.38,39 In a pancreas cancer 
cell line model, SP1 and KLF4 were reported to be important transcriptional 
regulators of KRT19, and in a breast cancer cell line model, HER2 was reported to 
be an important upstream regulator of KRT19. Nevertheless, these studies had several 
limitations: for one, they used relatively short (less than 2 kbp) mouse KRT19 
promoter constructs to search for transcriptional activators.40 Notwithstanding, 
because the expression of HER2 expression in HCC is not as high as breast cancer, 
these mechanisms may not to be a sufficient answer for KRT19 regulatory 
mechanisms in HCC.41
In our study, AP1 (JUN/FOSL1 complex) and SP1 transcription factors were 
identified as crucial positive regulators of KRT19 in HCC. SP1 was also reported as 
a transcriptional activator of mouse KRT19 promoter,38 and a previously reported SP1 
binding site in mouse KRT19 promoter was homologous with the SP1 binding site 
that we found in human KRT19 promoter (Figure 19). To our knowledge, the AP1 
binding site at 2kb upstream from the transcription start site has not been described 
previously. Interestingly, the AP1 binding site is very well conserved in most 
mammals, and the AP1 binding conservation is as well as protein coding region of 
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KRT19 (Figure 19), suggesting the functional importance of AP1-driven regulation 
of KRT19.
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Figure 18. Schematic representation of regulatory mechanism of KRT19 gene by 
cancer-associated fibroblast (CAF) derived HGF via MET-ERK1/2-AP1/SP1 
axis.
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Figure 19. Conservation of AP1 and SP1 binding sites in KRT19 promoter. The 
conservation status of the promoter and first exon and intron of KRT19. The figure 
was modified from the UCSC genome browser (http://genome.ucsc.edu). The 
conservation score was calculated from 100 vertebrate species, measured by 
phastCons from the PHAST package. Multiple alignment of representative mammals 
and other vertebrae also exhibited the conservation status of AP1 and SP1 sites.
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Previously, it was reported that a subset of HCC that exhibits a progenitor-like gene 
expression pattern, namely hepatoblast signature, comprises a poor prognosis.42 In 
the aforementioned study, HCC with hepatoblast signature was highly expressed in
hepatic stem cells, as was KRT19, and AP1 transcription factor was suggested as a 
major driver of hepatoblast signature expression. Our results provide a functional 
connection between HCC with hepatoblast signature, AP1 transcription factor, and 
KRT19 expression. Recently, a study demonstrated the tumor-initiating capacity of 
HCC is regulated by cancer-associated fibroblast-derived HGF and a MET-FOSL1 
axis.43 Collectively, previous and current reports seem to suggest the importance of 
MET/HGF and AP1 signaling axis in regulation of stemness of HCC, as well as the 
value of KRT19 as a marker of stemness and tumor-initiating capacity.
MET is an emerging therapeutic target of HCC, and currently, several clinical trials 
are targeting the HGF/MET signaling axis.44 For optimal therapeutic application of 
MET inhibitors, selective enroll of patients with MET-addicted HCC is crucial. 
Unfortunately, there has been no validated immunohistochemical protocol with which 
to assess the activation status of MET.45 Considering the short half-life (less than 10 
mins) of phospho-MET, which we noted in our in vitro models, we doubt that a
reliable assessment of the phosphorylation status of MET could be performed in 
clinical samples, especially in paraffin-embedded ones. Instead, we suggest that 
membranous distribution of MET and HGF and relatively stable downstream targets,
including FOSL1 and KRT19, could serve as indirect markers of MET signaling 
activation.
In both our in vitro model and human HCC samples, HGF was mainly observed in 
epithelial tumor cells, not in cancer-associated fibroblasts, from which HGF is 
produced. However, subcellular distributions of HGF and MET differed between the 
in vitro and tissue samples: HGF and MET were mainly observed in intracellular 
space with the HCC cell lines and in the membrane of human HCC samples. The 
difference in subcellular location of HGF and MET might result from different 
dynamics in endocytosis-recycling of MET. The endocytosis of receptor tyrosine 
kinases is an important regulator of downstream signaling, and the endocytic pathway 
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is commonly deregulated in cancers.46 The dynamics of endocytosis and recycling of 
MET has been shown to play a significant role in signal output of MET and MET-
driven tumorigenesis.47,48 Further study is needed to outline MET trafficking in HCC 
and its role in MET signaling.
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V. CONCLUSION
The expression of KRT19 in HCC is regulated by cancer-associated fibroblasts in
HCC via a HGF-MET-ERK1/2-AP1 and SP1 axis. The positive 
immunohistochemical staining of HGF and/or MET in human HCC was correlated 
with expression of FOSL1 and KRT19. Our results provide insights into the 
molecular background of aggressive KRT19-positive HCC. The assessment of these 
markers could serve as activation markers for MET signaling and poor outcomes.
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ABSTRACT (IN KOREAN)
간세포암에서 섬유아세포 유래 간세포성장인자와
MET-ERK1/2-AP1/SP1 신호전달에 의한 KRT19의 발현 조절
<지도교수 박영년>
연세대학교 대학원 의과학과
이형진
Keratin 19 (KRT19)는 간의 줄기세포/전구세포 표지자이며,
간암의 불량한 예후를 나타내는 인자로 잘 알려져 있음. 본
연구진은 풍부한 섬유성 기질을 가진 간암의 아형 (경화성
간암)에서 KRT19의 발현이 높음을 보고한 바 있음. 그러나,
간암에서 KRT19의 발현 조절 기전은 잘 알려져 있지 아니함.
본 연구에서는 간성상세포주(hTERT-HSC)와 간암세포주(HepG2, 
SNU423) 사이의 분비 인자 상호 작용 모델을 이용하여 KRT19의
발현 조절 기전을 연구하였음. 또한 KRT19의 조절 기전을 인체
간암 조직 339례로 구성된 조직미세배열에서 검증하였음.
간성상세포주(hTERT-HSC)은 분비 인자를 통하여 두
간암세포주에서 KRT19의 전사 및 단백질 발현을 증가시켰음.
hTERT-HSC 유래 적응용배지에 포함된 간세포성장인자가 MET을
활성화시키며, 이에 따라 활성화된 MEK-ERK1/2 신호전달계에
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의하여 KRT19의 발현이 증가함. 루시페레이즈를 이용한
촉진염기서열 분석을 통하여 KRT19 촉진염기서열 중 AP1과 SP1 
전사인자 결합부위가 KRT19 조절에 중요함을 밝힘. ERK1/2 
신호전달계의 하위에 있는 JUN과 FOSL1 등의 AP1 전사인자와 SP1 
전사인자가 KRT19의 발현을 활성함을 밝힘. Sorafenib, 
crizotininb이 MET 또는 MEK-ERK1/2 신호전달계의 활성을
저해하여 적응용배지에 의한 KRT19 발현 증가를 저해할 수 있었음.
인체 간암 조직에서 면역 염색으로 단백질 발현을 확인한 결과, 
KRT19의 발현은 HGF, MET, FOSL1의 발현과 유의한 상관 관계를
보였으며, 간암에서 관찰된 암 연관 섬유아세포 양과도 유의한
상관을 보였음.
  결론적으로, 간암에서 KRT19의 발현은 간암의 암 연관
섬유아세포에 의하여 HGF-MET-ERK1/2-AP1/SP1 신호전달을 통하여
조절됨. 본 연구 결과는 임상적으로 불량한 예후를 보이는 KRT19 
양성 간암의 분자적 특성을 이해할 수 있도록 함.
핵심되는 말: Keratin 19, 암 연관 섬유아세포, 간세포성장인자,
MET, Fos-related antigen 1
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